Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating pegcetacoplan for adults at high risk of delayed graft function after kidney transplantation is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function
• End-stage Renal Disease

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Delayed Graft Function, End Stage Renal Disease | Phase 3 | Status: RECRUITING